Health Care's Elite Eight Stocks: Celgene vs. Gilead

Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means that Cinderella stories like Wichita State have busted brackets of would-be basketball prognosticators.

Here at The Motley Fool, we decided to stick with what we know -- trading our basketball picks in for stock picks. We formed our own bracket filled with the top big pharma and big biotech stocks in a winner-take-all tournament determined by the collective intelligence of our CAPS community.

This Elite 8 matchup features a heavyweight bought between Celgene and Gilead. Watch and find out which stock gets eliminated and which will advance to the next round.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today simply click here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2343886, ~/Articles/ArticleHandler.aspx, 4/23/2014 5:20:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement